As of 2025-04-25, the Relative Valuation of Atea Pharmaceuticals Inc (AVIR) is (31.11) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.87 USD, the upside of Atea Pharmaceuticals Inc based on Relative Valuation is -1183.8%.
The range of the Relative Valuation is (26.89) - (33.67) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.7x - 17.1x | 15.9x |
| Forward P/E multiples | 12.0x - 17.6x | 15.7x |
| Fair Price | (26.89) - (33.67) | (31.11) |
| Upside | -1037.0% - -1273.0% | -1183.8% |
| Date | P/E |
| 2025-04-21 | -1.45 |
| 2025-04-17 | -1.51 |
| 2025-04-16 | -1.52 |
| 2025-04-15 | -1.43 |
| 2025-04-14 | -1.49 |
| 2025-04-11 | -1.38 |
| 2025-04-10 | -1.37 |
| 2025-04-09 | -1.39 |
| 2025-04-08 | -1.35 |
| 2025-04-07 | -1.41 |
| 2025-04-04 | -1.42 |
| 2025-04-03 | -1.47 |
| 2025-04-02 | -1.46 |
| 2025-04-01 | -1.45 |
| 2025-03-31 | -1.52 |
| 2025-03-28 | -1.49 |
| 2025-03-27 | -1.53 |
| 2025-03-26 | -1.62 |
| 2025-03-25 | -1.63 |
| 2025-03-24 | -1.63 |
| 2025-03-21 | -1.64 |
| 2025-03-20 | -1.60 |
| 2025-03-19 | -1.61 |
| 2025-03-18 | -1.61 |
| 2025-03-17 | -1.59 |
| 2025-03-14 | -1.56 |
| 2025-03-13 | -1.55 |
| 2025-03-12 | -1.57 |
| 2025-03-11 | -1.48 |
| 2025-03-10 | -1.48 |
| 2025-03-07 | -1.52 |
| 2025-03-06 | -1.52 |
| 2025-03-05 | -1.53 |
| 2025-03-04 | -1.47 |
| 2025-03-03 | -1.47 |
| 2025-02-28 | -1.54 |
| 2025-02-27 | -1.55 |
| 2025-02-26 | -1.61 |
| 2025-02-25 | -1.59 |
| 2025-02-24 | -1.59 |
| 2025-02-21 | -1.57 |
| 2025-02-20 | -1.59 |
| 2025-02-19 | -1.57 |
| 2025-02-18 | -1.57 |
| 2025-02-14 | -1.60 |
| 2025-02-13 | -1.58 |
| 2025-02-12 | -1.58 |
| 2025-02-11 | -1.52 |
| 2025-02-10 | -1.54 |
| 2025-02-07 | -1.51 |